**INTRODUCTION:** Periorbital volume loss contributes significantly to facial aging and can result in tear trough deformities and infero-lateral skeletonization of the orbit. Tear trough augmentation with injectable hyaluronic acid based filler is an established technique for augmenting periorbital volume loss, but it has thus far been limited by swelling, contour abnormalities, and the Tindell effect. Juvederm Volbella (Allergan Inc., Irvine, CA, USA) is a new 15 mg/mL hyaluronic acid dermal filler formulated using a majority of low molecular weight hyaluronic acid and a minority of high molecular weight hyaluronic acid for tighter cross-linking ("VYCROSS"). As a hydrophilic, malleable, homogenous matrix, the rheology of Volbella allows it to distribute evenly in treated tissue beds.

**PURPOSE:** To date, tear trough augmentation has most commonly been performed with Restylane, Belotero, and Juvederm. In this paper, we studied Volbella, which has been FDA approved for lip augmentation and perioral rhytids, for off-label use in tear trough augmentation.

**METHODS:** A retrospective chart review was conducted on a cohort of all periorbital aging patients in a single-surgeon practice who underwent tear trough augmentation using Volbella. Patients who underwent tear trough augmentation with other dermal fillers or with autologous fat grafting were excluded. Mean follow up time was 2 weeks.

**RESULTS:** 81 patients met inclusion criteria and were included in this technique analysis. Of those, 2 had had previous lower eyelid blepharoplasties. Patients were treated with between 0.55cc and 1.65cc of Volbella. All patients had uneventful procedural courses. Post-procedure, 7 patients (8.6%) reported swelling, and 5 (6.1%) required an oral course of methylprednisolone to reduce inflammation. No patients experienced the Tindell effect or contour abnormalities, and no patients required dissolution of filler. There were no instances of skin necrosis, tissue injury, or intravascular injection. All 81 patients were satisfied with their aesthetic results, and no patients requested or were advised to have filler dissolution.

**CONCLUSION:** Volbella is a safe and effective option for tear trough augmentation.
